Holding(s) in Company

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

SkyePharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

Frank Condella

(Chairman of SkyePharma PLC and proxy holder)

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

10 May 2010

6. Date on which issuer notified:

10 May 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

3%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B3BFNB64

Below 3%

Below 3%

0

0

4,856,751

0

20.28%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

4,856,751

20.28

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting:

10. Name of the proxy holder:

Frank Condella

11. Number of voting rights proxy holder will cease to hold:

4,856,751

12. Date on which proxy holder will cease to hold voting rights:

At the conclusion of the Annual General Meeting to be held on 12 May 2010 or at any adjournment thereof

13. Additional information:

Disclosed voting rights represent the maximum number of proxies held by the Chairman of SkyePharma PLC pursuant to proxies received in respect of the various resolutions to be proposed at the Annual General Meeting to be held on 12 May 2010 or at any adjournment thereof. The voting rights will lapse immediately upon the conclusion of the Annual General Meeting.

14. Contact name:

John Murphy

15. Contact telephone number:

020 7491 1777